# A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors

> **NCT07647042** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 750 (actual)

## Conditions studied

- Breast Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07647042
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2026-03-31
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 750 (ACTUAL)
- **Last updated:** 2026-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07647042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07647042, "A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07647042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*